Literature DB >> 15236754

Characterization of the immunoreactivity of anti-interferon alpha antibodies in myasthenia gravis patients. Epitope mapping.

Iraldo Bello-Rivero1, Majel Cervantes, Yeny Torres, Joel Ferrero, Eulises Rodríguez, Jesús Pérez, Idrian García, Gisou Díaz, Pedro López-Saura.   

Abstract

Cytokines, such as interferons (IFN), underlie many immunological functions and are increasingly implicated in disease-related symptoms and pathology. In order to study the potential roles of IFN alpha and its antagonists in autoimmune phenomena, the sera from 89 patients (aged 15-95 years, 65 females) diagnosed as having myasthenia gravis (MG) (2 months to 34 years duration) were tested for the presence of natural anti-IFN alpha-2b auto-antibodies. Sera were screened for anti-IFN alpha-2b by a sandwich-type enzyme immunoassay system. Ten (11.2%) and 6 (6.7%) sera were identified that contained positive-competing and non-competing anti-IFN alpha-2b auto-antibodies, respectively. The MG sera were further analyzed by immunobloting against reduced IFN alpha-2b and for neutralizing anti-IFN alpha activity in an antiviral assay cells system. From tested EIA positive-competing sera, 5 were shown to be positive by immunoblot and 6 sera were found to contain neutralizing anti-IFN alpha-2b. Four of the 6 neutralizing anti-IFN alpha-2b sera came from patients with thymoma-associated MG. The sera were studied for linear epitope recognition on the IFN alpha-2b molecule by a solid phase binding assay, in which overlapping peptides homologous with the entire IFN alpha-2b sequence were separately synthesized on a nitrocellulose sheet. Peptides number 2 (residues 8-21), 3 (15-28), 6 (33-46), 10 (63-76), 15 (98-112), and 21 (141-154) were immunoreactive. Peptide 21 was apparently associated with antiviral activity, although peptide 21 has not been previously described as an immunogenic determinant on the IFN alpha-2b molecule. These results indicate that neutralizing anti-IFN alpha-2b is often present in MG, particularly in cases of thymoma-associated MG, and recognize a variety of epitopes on the IFN alpha-2b molecule, including those involved in its biological activity. Two groups of IFN epitopes were described associated with patient's age but not with diseases evolution. Copyright 2004 Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15236754     DOI: 10.1016/j.jaut.2004.03.013

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  7 in total

1.  Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.

Authors:  Adrian Gervais; Tom Le Voyer; Jérémie Rosain; Quentin Philippot; Jérémy Manry; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Shohei Eto; Marina Garcia-Prat; Lucy Bizien; Alba Parra-Martínez; Rui Yang; Liis Haljasmägi; Mélanie Migaud; Karita Särekannu; Julia Maslovskaja; Evangelos Vandreakos; Olivier Hermine; Aurora Pujol; Pärt Peterson; Trine H Mogensen; Lee Rowen; James Mond; Xavier de Lamballerie; Xavier Duval; France Mentré; Marie Zins; Pere Soler-Palacin; Roger Colobran; Guy Gorochov; Xavier Solanich; Sophie Susen; Javier Martinez-Picado; Didier Raoult; Marc Vasse; Peter K Gregersen; Lorenzo Piemonti; Carlos Rodríguez-Gallego; Luigi D Notarangelo; Helen C Su; Kai Kisand; Satoshi Okada; Anne Puel; Emmanuelle Jouanguy; Charles M Rice; Pierre Tiberghien; Qian Zhang; Aurélie Cobat; Laurent Abel; Jean-Laurent Casanova; Paul Bastard; Nicolas de Prost; Yacine Tandjaoui-Lambiotte; Charles-Edouard Luyt; Blanca Amador-Borrero; Alexandre Gaudet; Julien Poissy; Pascal Morel; Pascale Richard; Fabrice Cognasse; Jesus Troya; Sophie Trouillet-Assant; Alexandre Belot; Kahina Saker; Pierre Garçon; Jacques G Rivière; Jean-Christophe Lagier; Stéphanie Gentile; Lindsey B Rosen; Elana Shaw; Tomohiro Morio; Junko Tanaka; David Dalmau; Pierre-Louis Tharaux; Damien Sene; Alain Stepanian; Bruno Megarbane; Vasiliki Triantafyllia; Arnaud Fekkar; James R Heath; José Luis Franco; Juan-Manuel Anaya; Jordi Solé-Violán; Luisa Imberti; Andrea Biondi; Paolo Bonfanti; Riccardo Castagnoli; Ottavia M Delmonte; Yu Zhang; Andrew L Snow; Steven M Holland; Catherine Biggs; Marcela Moncada-Vélez; Andrés Augusto Arias; Lazaro Lorenzo; Soraya Boucherit; Boubacar Coulibaly; Dany Anglicheau; Anna M Planas; Filomeen Haerynck; Sotirija Duvlis; Robert L Nussbaum; Tayfun Ozcelik; Sevgi Keles; Ahmed A Bousfiha; Jalila El Bakkouri; Carolina Ramirez-Santana; Stéphane Paul; Qiang Pan-Hammarström; Lennart Hammarström; Annabelle Dupont; Alina Kurolap; Christine N Metz; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Fabio Ciceri; Lucila A Barreiros; Elena Dominguez-Garrido; Mateus Vidigal; Mayana Zatz; Diederik van de Beek; Sabina Sahanic; Ivan Tancevski; Yurii Stepanovskyy; Oksana Boyarchuk; Yoko Nukui; Miyuki Tsumura; Loreto Vidaur; Stuart G Tangye; Sonia Burrel; Darragh Duffy; Lluis Quintana-Murci; Adam Klocperk; Nelli Y Kann; Anna Shcherbina; Yu-Lung Lau; Daniel Leung; Matthieu Coulongeat; Julien Marlet; Rutger Koning; Luis Felipe Reyes; Angélique Chauvineau-Grenier; Fabienne Venet; Guillaume Monneret; Michel C Nussenzweig; Romain Arrestier; Idris Boudhabhay; Hagit Baris-Feldman; David Hagin; Joost Wauters; Isabelle Meyts; Adam H Dyer; Sean P Kennelly; Nollaig M Bourke; Rabih Halwani; Narjes Saheb Sharif-Askari; Karim Dorgham; Jérome Sallette; Souad Mehlal Sedkaoui; Suzan AlKhater; Raúl Rigo-Bonnin; Francisco Morandeira; Lucie Roussel; Donald C Vinh; Sisse Rye Ostrowski; Antonio Condino-Neto; Carolina Prando; Anastasiia Bonradenko; András N Spaan; Laurent Gilardin; Jacques Fellay; Stanislas Lyonnet; Kaya Bilguvar; Richard P Lifton; Shrikant Mane; Mark S Anderson; Bertrand Boisson; Vivien Béziat; Shen-Ying Zhang; Stéphanie Debette
Journal:  Sci Immunol       Date:  2021-08-19

Review 2.  Human genetic and immunological determinants of critical COVID-19 pneumonia.

Authors:  Qian Zhang; Paul Bastard; Aurélie Cobat; Jean-Laurent Casanova
Journal:  Nature       Date:  2022-01-28       Impact factor: 69.504

3.  Anti-chemokine antibodies after SARS-CoV-2 infection correlate with favorable disease course.

Authors:  Jonathan Muri; Valentina Cecchinato; Andrea Cavalli; Akanksha A Shanbhag; Milos Matkovic; Maira Biggiogero; Pier Andrea Maida; Chiara Toscano; Elaheh Ghovehoud; Gabriela Danelon-Sargenti; Tao Gong; Pietro Piffaretti; Filippo Bianchini; Virginia Crivelli; Lucie Podešvová; Mattia Pedotti; David Jarrossay; Jacopo Sgrignani; Sylvia Thelen; Mario Uhr; Enos Bernasconi; Andri Rauch; Antonio Manzo; Adrian Ciurea; Marco B L Rocchi; Luca Varani; Bernhard Moser; Marcus Thelen; Christian Garzoni; Alessandra Franzetti-Pellanda; Mariagrazia Uguccioni; Davide F Robbiani
Journal:  bioRxiv       Date:  2022-05-23

4.  A robust immunoassay for anti-interferon autoantibodies that is highly specific for patients with autoimmune polyglandular syndrome type 1.

Authors:  Li Zhang; Jennifer M Barker; Sunanda Babu; Maureen Su; Matthew Stenerson; Mickie Cheng; Anthony Shum; Ehud Zamir; Raffaele Badolato; Adam Law; George S Eisenbarth; Mark S Anderson
Journal:  Clin Immunol       Date:  2007-09-06       Impact factor: 3.969

5.  Direct proof of the in vivo pathogenic role of the AChR autoantibodies from myasthenia gravis patients.

Authors:  Gregory Kordas; George Lagoumintzis; Sotirios Sideris; Konstantinos Poulas; Socrates J Tzartos
Journal:  PLoS One       Date:  2014-09-26       Impact factor: 3.240

6.  Human autoantibodies underlying infectious diseases.

Authors:  Anne Puel; Paul Bastard; Jacinta Bustamante; Jean-Laurent Casanova
Journal:  J Exp Med       Date:  2022-03-23       Impact factor: 14.307

7.  Autoantibodies against type I IFNs in patients with critical influenza pneumonia.

Authors:  Qian Zhang; Andrés Pizzorno; Lisa Miorin; Paul Bastard; Adrian Gervais; Tom Le Voyer; Lucy Bizien; Kai Kisand; Anne Puel; Emmanuelle Jouanguy; Laurent Abel; Aurélie Cobat; Sophie Trouillet-Assant; Adolfo García-Sastre; Jean-Laurent Casanova; Jeremy Manry; Jérémie Rosain; Quentin Philippot; Kelian Goavec; Blandine Padey; Anastasija Cupic; Emilie Laurent; Kahina Saker; Martti Vanker; Karita Särekannu; Tamara García-Salum; Marcela Ferres; Nicole Le Corre; Javier Sánchez-Céspedes; María Balsera-Manzanero; Jordi Carratala; Pilar Retamar-Gentil; Gabriela Abelenda-Alonso; Adoración Valiente; Pierre Tiberghien; Marie Zins; Stéphanie Debette; Isabelle Meyts; Filomeen Haerynck; Riccardo Castagnoli; Luigi D Notarangelo; Luis I Gonzalez-Granado; Nerea Dominguez-Pinilla; Evangelos Andreakos; Vasiliki Triantafyllia; Carlos Rodríguez-Gallego; Jordi Solé-Violán; José Juan Ruiz-Hernandez; Felipe Rodríguez de Castro; José Ferreres; Marisa Briones; Joost Wauters; Lore Vanderbeke; Simon Feys; Chen-Yen Kuo; Wei-Te Lei; Cheng-Lung Ku; Galit Tal; Amos Etzioni; Suhair Hanna; Thomas Fournet; Jean-Sebastien Casalegno; Gregory Queromes; Laurent Argaud; Etienne Javouhey; Manuel Rosa-Calatrava; Elisa Cordero; Teresa Aydillo; Rafael A Medina
Journal:  J Exp Med       Date:  2022-09-16       Impact factor: 17.579

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.